What happened with MLAB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Mesa Laboratories supplies pharmaceutical companies, medical-device manufacturers, healthcare providers and research laboratories with products for checking production processes and conducting research. Its largest business sells disposable indicators used to assess sterilization, disinfection and cleaning, alongside laboratory testing services. Customers use these indicators routinely and buy replacements as they are consumed.
Mesa also sells instruments for protein analysis, peptide production and genetic research, including the MassARRAY genetic-analysis system. Customers buy associated consumables to keep using these instruments and pay for maintenance and support. MassARRAY serves research rather than diagnostic testing. A separate calibration business sells instruments, monitoring systems and dialysis calibration supplies to customers that need accurate measurements and periodic checks to meet quality-control and regulatory requirements. Across Mesa, consumables generate most revenue; equipment sales and services provide the rest.
Repeat purchasing is important, but customer concentration varies by business: Clinical Genomics earns most of its revenue from consumables and relies heavily on ongoing purchases by a small group of key customers. Equipment demand also depends on customers’ capital budgets. Some Mesa products are regulated medical devices, so selling new or modified products, or expanding their uses, can require FDA or foreign regulatory authorization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
STERIS and Mesa compete for healthcare, pharmaceutical and medical-device customers buying products that check sterilization and laboratory testing services. Watch STERIS's sterilization consumables and testing business for clues to demand in Mesa's Sterilization and Disinfection Control division, which generated 40.8% of its reportable-segment revenue in fiscal 2026.
Fortive overlaps Mesa in two areas of healthcare spending: sterilization and testing medical equipment, where Mesa sells sterilization checks and medical calibration products. Fortive's sterilization and biomedical-testing business is the part to watch, rather than its broader industrial instruments and software.
Sotera Health Company competes with Mesa for pharmaceutical and medical-device customers' laboratory testing work that checks for microbial contamination. Its microbiological testing business is the closer read-through for Mesa's sterility-assurance services, distinct from Sotera's work sterilizing products in their final packaging.
Revvity and Mesa compete for pharmaceutical, contract-research and academic laboratories buying protein and genetic research instruments and consumables. Revvity's Life Sciences business is the relevant watchpoint for Mesa's research sales, rather than its diagnostic testing business.
Thermo Fisher Scientific competes with Mesa for research customers buying instruments and consumables to analyze genes and proteins. Those product lines, sold to pharmaceutical companies and research laboratories, are the relevant comparison for Mesa's research systems.
Danaher's life-sciences businesses sell systems for studying proteins and analyzing molecules to research customers also served by Mesa. That overlap makes Danaher's research systems a comparison for Mesa's protein-analysis business, rather than its entire biotechnology and diagnostics portfolio.
Agilent and Mesa compete for life-sciences laboratories buying genetic and biomolecular analysis instruments, consumables and services. Separate Agilent's instrument demand from CrossLab consumables: most of that consumables portfolio works across instrument brands, so its sales need not track Agilent's own equipment sales.
Bruker and Mesa compete for life-sciences and biopharmaceutical researchers' spending on instruments that analyze molecules and biological samples. Watch Bruker's offerings for those researchers: it identifies performance and cost-effectiveness as key factors in winning instrument purchases.
Mettler-Toledo serves research and manufacturing work that also needs Mesa's calibration and monitoring products, linking both to laboratory and quality-control spending. Its laboratory instruments and related services are the useful demand gauge for Mesa, whose customers must periodically calibrate and validate equipment to meet quality and regulatory requirements.
Repligen and Mesa both serve biological-drug development and manufacturing, but sell different tools: Repligen supplies production systems, while Mesa sells systems that measure proteins during development and processing. Repligen's filtration and process-analysis business offers a view of activity among the biologic-drug manufacturers Mesa serves.
Waters and Mesa share exposure to biopharmaceutical laboratories' equipment spending: Waters sells systems that separate and identify sample components, while Mesa sells genetic and protein-analysis systems. Watch Waters's instrument sales separately from maintenance and support, which accounted for over 35% of its sales in 2025.
Cytek Biosciences and Mesa rely on the same pharmaceutical, contract-research and academic sectors buying research tools: Cytek analyzes cells, while Mesa analyzes proteins and genes. Cytek's instrument demand is a useful check on discretionary equipment spending, which supplied approximately 40% of Mesa's Biopharmaceutical Development revenue in fiscal 2026.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher’s report will show what research customers’ spending on gene- and protein-analysis instruments and consumables says about the market for Mesa Laboratories’ research systems.
Compare Thermo Fisher’s instrument sales with its consumables sales. If both hold up, research customers are still buying systems and using them; if instruments weaken while consumables hold, customers may be using existing equipment but delaying new systems, putting more pressure on demand for Mesa’s protein- and genetic-analysis hardware. Thermo Fisher’s sales show the shared market, not how many orders Mesa wins.
Fed Interest Rate Decision
Fed rate decisions matter to Mesa Laboratories because its variable-rate Credit Facility reprices with market rates, changing interest paid on its outstanding revolver and leaving less or more income after interest.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can raise interest on Mesa’s variable-rate borrowing, leaving less of its operating income after debt service and potentially reducing net income.
If it comes in below expectations
Lower rates can reduce interest on Mesa’s variable-rate borrowing, leaving more of its operating income after debt service and potentially supporting net income.
Cytek Biosciences, Inc. earningsCTKB
Cytek Biosciences’ instrument demand will show whether pharmaceutical, contract-research and academic customers also served by Mesa Laboratories are still buying research equipment.
Watch Cytek Biosciences’ instrument demand. If it holds up, shared customers are still buying research equipment, a supportive sign for demand for the more discretionary hardware in Mesa’s Biopharmaceutical Development business. If it weakens, customers may be delaying equipment purchases, putting Mesa’s instrument sales under pressure too, though Cytek’s results alone cannot establish what happened to Mesa’s orders.
STERIS plc earningsSTE
STERIS’s sterilization consumables and testing business will show how demand is changing in the market served by Mesa Laboratories’ largest division.
Read STERIS’s sterilization consumables and testing business together. If both hold up, pharmaceutical, medical-device and healthcare customers are still buying related products and services, supporting demand in Mesa’s Sterilization and Disinfection Control division. If both weaken, that division faces a softer customer backdrop. STERIS’s sales reflect the shared market, not a change in Mesa’s market share.
Mesa Laboratories Inc earningsThis company
Mesa Laboratories’ report will show whether consumables sales are supporting demand and whether growth is reaching beyond its largest division, Sterilization and Disinfection Control.
Read consumables revenue alongside hardware and software revenue, then check sales across the four divisions. Steady consumables sales with growth beyond Sterilization and Disinfection Control would show repeat use supporting demand more broadly. If growth comes mainly from that division while hardware or other divisions weaken, demand is still concentrated rather than broadening across Mesa’s products.
Mettler-Toledo International earningsMTD
Mettler-Toledo’s laboratory instrument and related service sales will show whether quality-control spending connected to Mesa Laboratories’ calibration and monitoring business is holding up.
Compare Mettler-Toledo’s laboratory instrument sales with its related service sales. If both hold up, laboratories and manufacturers are still investing in equipment and maintaining or using what they have, a supportive sign for the quality-control market around Mesa’s calibration and monitoring products and services. If instruments weaken while services hold, customers may be maintaining existing equipment but delaying new purchases. Mettler-Toledo is a market signal, not a substitute for Mesa’s own sales.
